Orthofix Medical Inc. (NASDAQ:OFIX) Given Average Rating of “Moderate Buy” by Analysts

Shares of Orthofix Medical Inc. (NASDAQ:OFIX) have received an average recommendation of “Moderate Buy” from the five research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $23.33.

OFIX has been the topic of a number of recent analyst reports. StockNews.com raised Orthofix Medical from a “hold” rating to a “buy” rating in a report on Tuesday, February 25th. Canaccord Genuity Group reissued a “buy” rating and issued a $24.00 price target on shares of Orthofix Medical in a report on Wednesday, February 26th. Finally, Roth Mkm reaffirmed a “buy” rating and set a $22.00 price objective on shares of Orthofix Medical in a report on Wednesday, February 26th.

Insider Activity at Orthofix Medical

In other news, CFO Julie Andrews sold 4,655 shares of the business’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $17.89, for a total value of $83,277.95. Following the sale, the chief financial officer now directly owns 28,312 shares in the company, valued at $506,501.68. The trade was a 14.12 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Massimo Calafiore sold 10,078 shares of the stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $16.83, for a total transaction of $169,612.74. Following the completion of the transaction, the chief executive officer now directly owns 133,354 shares of the company’s stock, valued at approximately $2,244,347.82. The trade was a 7.03 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,075 shares of company stock valued at $513,693. 2.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Orthofix Medical

Institutional investors and hedge funds have recently modified their holdings of the stock. Lazard Asset Management LLC purchased a new stake in Orthofix Medical during the 4th quarter valued at $45,000. R Squared Ltd purchased a new stake in shares of Orthofix Medical in the fourth quarter valued at $50,000. KLP Kapitalforvaltning AS bought a new stake in shares of Orthofix Medical in the 4th quarter worth about $112,000. Tower Research Capital LLC TRC boosted its stake in shares of Orthofix Medical by 120.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,458 shares of the medical device company’s stock worth $148,000 after purchasing an additional 4,627 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Orthofix Medical by 5.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,994 shares of the medical device company’s stock valued at $156,000 after purchasing an additional 559 shares during the last quarter. Hedge funds and other institutional investors own 89.76% of the company’s stock.

Orthofix Medical Price Performance

Shares of NASDAQ:OFIX opened at $14.58 on Monday. The company has a market capitalization of $568.94 million, a P/E ratio of -4.66 and a beta of 0.99. Orthofix Medical has a 1-year low of $12.08 and a 1-year high of $20.73. The firm’s 50 day simple moving average is $17.38 and its two-hundred day simple moving average is $17.34. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.39 and a quick ratio of 1.11.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.